Skip to main content
. 2021 Jan 11;11:609941. doi: 10.3389/fimmu.2020.609941

Figure 8.

Figure 8

Complement dependent lysis and C3b deposition on primary human chronic lymphocytic leukemia (CLL) B cells. Complement-dependent cytotoxicity (CDC) and C3b deposition were compared for primary human B cells derived from CLL patients with distinct expression profiles of CD20 and CD59 upon treatment with 20 µg/ml Rituximab (RTX), Ofatumumab (OFA), or Obinutuzumab (OBI) in absence (white) or presence of 20% normal (NHS, black) or heat-inactivated (HIS, gray) human serum for 30 min at 37°C. (A) Flow cytometry expression analysis of CD19 and CD20, FcγRIIb, CD55, and CD59 on CD19+ cells of healthy (HD) or CLL B cells. (B) Exemplary dot plots of CD19 and DAPI staining. (C) Quantification of living CD19+DAPI- cells for three to four sera. (D) Quantification of C3b/iC3b deposition on CD19+ cells. Bars show mean ± standard deviation of three to four serum samples. For statistical analysis, Mann Whitney test (A) or two-way ANOVA and Sidak´s multiple comparison test (C, D) were applied. *p<0.05, **p<0.01, ****p<0.0001.